GALAXY Medical CENTAURI PEF Generator to be Used During Recorded Case Presentation at AF Symposium
SAN CARLOS, California, January 18, 2021 — Galaxy Medical, a developer of Pulsed Electric Field (PEF) technology for the treatment of cardiac arrhythmias, today announced that its proprietary CENTAURI™ System will be featured in a recorded case presentation on Sunday January 31st during the upcoming AF Symposium.
Ante Ani, EP Lab Director at University Hospital Split and the Primary Investigator of the ECLIPSE-AF study will be presenting the case which was completed as part of the ECLIPSE-AF study. Dr. Ani said: “The Galaxy Medical CENTAURI System has performed extremely well during the first 31 cases we have completed at our center and we felt this was a unique opportunity to share our experience with the EP community.”
Jeremy Ruskin, MD, Medical Director of the AF Symposium commented “It is always wonderful to be able to share promising new technologies with our EP colleagues and we are excited about our new virtual format this year. We believe we have a world class 3 day program starting on January 29th and look forward to a great event.”
The CENTAURI System is uniquely designed as an open energy platform with proprietary interface hardware and waveform control algorithms, which enable electrophysiologists to continue with the established point-by-point clinical workflow used in the majority of cardiac ablation procedures worldwide. Centauri offers the enhanced features of PEF energy without the typical learning curve and workflow adjustments associated with new technologies.
Key features of the CENTAURI System:
- Plug and play with standard electrophysiology workflows, cardiac mapping and navigation systems
- No compromise compatibility with market-released focal and contact force sensing catheters
- Physician choice of dose setting when treating variable tissue thickness
- Proprietary technology that completely eliminates micro-bubbles during PEF delivery
- Automated output control to prevent overdosing or under-dosing
Jonathan Waldstreicher, MD, CEO of Galaxy Medical commented: “We are very pleased that through the collaboration with Dr. Anic and Dr. Ruskin, we have this opportunity, to give the EP community an early look at our system, at such a prominent event as the 2021 AF Symposium. Our ECLIPSE-AF trial has been going extremely well with 47 patients already treated, despite all the challenges around COVID-19, and more to come in the next few months. We look forward to continuing collaboration with electrophysiologists in Europe and the US during our imminent CE Submission and pending US IDE trial later this year.”
CENTAURI is an investigational device and not commercially available.